bullish
Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T
365 Views01 Jun 2020 14:59
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, started book building to raise up to USD 368 million via an IPO. The company has a...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction26 Jul 2022
- Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise15 Dec 2021
- Legend Biotech (传奇生物) IPO Trading: +27% Upside from Pricing05 Jun 2020
- Legend Biotech (传奇生物) Pre-IPO: Superior Efficacy Vs Bluebird/BMS Candidate26 May 2020
- Legend Biotech (传奇生物) Pre-IPO: All-Stars Except for the Small Indication19 May 2020
x